Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli Lilly told CNBC, "Lilly will continue to work with those in health care, government and the ...